通过^131I标记藤黄酸以分析其在肿瘤细胞中的摄取及动物体内的分布。采用双氧水标记、氯仿萃取,以聚酰胺薄膜为支持介质、氯仿-甲醇(体积比为40∶1)为展开剂,测定标记率及放化纯;分析肿瘤细胞MCF-7对^131I-藤黄酸的摄取;KM小鼠尾静脉注射^131I-藤黄酸(每只185 kBq),于不同时间处死,取各脏器,称重、测量计数率,计算每克组织百分注射剂量率。^131I-藤黄酸标记率达86%,放化纯在1,4,20 d分别为97.2%,95.4%,93.3%;MCF-7在30 min时对^131I-藤黄酸摄取率达3.50%,显著高于对Na^131I的摄取(P〈0.01);^131I-藤黄酸在体内分布广泛,以肝、肾和肠为最多,肝中5 min时放射性摄取达25.93%ID/g,4 h则为5.54%ID/g,而肾中5 min时为6.37%ID/g,4 h时为2.46%ID/g;甲状腺中的放射性摄取随时间的延长而增加.^131I-藤黄酸标记物稳定;肿瘤细胞MCF-7对^131I-藤黄酸有显著摄取;体内主要通过肝肾代谢。
The preparation of radioiodinated gambogic acid and its cell uptake in MCF-7 and bio distribution in mice were investigated. Gambogic acid was labeled with ^131I using hydrogen peroxide. The radiolabeled compound was characterized by polyamide TLC, in which the substratum of V(trichoromethane ) : V( methanol ) =40 : 1 was used as developing agent. The uptake of ^131 I-gambogic acid in cancer ceils was measured. Biodistribution studies were carried out in KM mice. At different time after radiopharmaceutical i. v. administration (185 kBq ^131I-gambogic acid /mouse), the animals were sacrificed. Blood samples and the tissues of interested were collected, weighted and counted. The percent injected dose per gram (%ID/g) was calculated for each sample. The labeling yield of ^131I-gambogic acid is 86% and its radiochemistry purity are 97. 2%, 95. 4%, and 93.3% at 1, 4, and 20 d, respectively. The uptake of ^131I- gambogic acid in MCF-7 shows markedly higher compared with Na^131 I(P〈0.01). The in vivo biodistribution in mice indicates that ^131I-gambogic acid is mainly uptaked in liver, kidney, and intestines. The radioactivity in thyroid increases with time. ^131I-gambogic acid is stable and is markedly uptaked in cancer cells MCF-7. In mice, it is mainly metabolized by liver and excreted through kidney.